Targeting acquired resistance mutations in tumors using self-replicating RNA: A Phase I trial of RBI1000, a srRNA vaccine, as a monotherapy and in combination in endocrine resistant advanced and metastatic breast cancer
We use cookies to keep your session secure, remember your preferences, and analyse site traffic with Google Analytics.
By continuing to use GrantFunds you agree to our
Privacy Policy
and
Terms of Use.